Abeona Therapeutics’ Post

[BLOG POST] Dive Deeper into the Future of Therapeutics! Get ready for the next part of our ground-breaking blog series - 'The Future is Non-Viral,' where we delve even further into the exciting realm of therapeutic advancements. In this sequel, we continue to explore the insights shared by Ken LeClair, Chair of RoslinCT’s Scientific Advisory Board, uncovering the transformative potential of non-viral vector alternatives. Discover how cutting-edge cellular reprogramming techniques are revolutionizing the field and learn about the latest advancements that are reshaping tomorrow's therapies. Read the blog post: https://lnkd.in/ehQxp_an #TherapeuticDelivery #SABPerspectives #Roslinsights

Extracellular vesicles (EVs) are garnering immense interest for their potential in diagnostics, therapeutics, and as biomarkers for a myriad of diseases. As the research community delves deeper into the microscopic marvels of EVs, the demand for technology advancement has surged. Learn more about how innovative tools from BD Biosciences can help you accelerate your discoveries. https://lnkd.in/em_yzWTM #BDBiosciences #flowcytometry #FACS

This is a very flexible platform for screening and optimisation of small molecules directly against whole organism models..

It was very exciting to participate in this panel discussion at the Main Stage during #SynBioBeta2024 last week in sunny San Jose. Thanks to John Cumbers and his team for putting together another amazing conference; and to Meenakshi Prabhune, PhD for moderating this session on the present and future of Targeted Therapeutics, with insights from peer panelist Mark Kotter, Anil Narasimha and Daniel Georgiev. What an exiciting field #GeneWriting is for unlocking the full potential of #AdvancedTherapies.

Producing consistent results is the most effective way to get funding and get published. Get consistent results by using a Singulator for your sample prep.

Today, we are sharing our CEOs thoughts on a recent exciting industry development

🧠 Amyotrophic Lateral Sclerosis (ALS) is a rare and fatal neurodegenerative disease with limited treatment options. We are progressing our asset BEN-34712 to its next inflection point. 👉 BenevolentAI has a rich drug pipeline of high-potential clinical and preclinical assets. 🚀 To learn more about licensing and commercialisation for specific assets within our pipeline, contact our team: bd@benevolent.ai  

Curious about the groundbreaking advancements in microbiome-based therapeutics? Explore the insights shared by our Chief Scientific Officer, Christopher Weidenmaier, PhD, and Chief Technology Officer, Johannes B. Woehrstein, PhD, as they discuss the challenges and considerations in manufacturing LBPs 🧪 The journey to harnessing the power of the human microbiome is both exhilarating and complex. Discover the remarkable efficacy of complex live biotherapeutic products (LBPs) in modulating the microbiome, evidenced by the recent approvals of Rebyota and VOWST. Read the full article on EPR to uncover the future of microbiome-based treatments: https://bit.ly/4bhMqAw #LBPs #MicrobiomeTherapeutics #BiotechInnovation #ScienceAndTechnology #EPR

INDUSTRY NEWS - CAR-T in autoimmunity My thoughts on the news 'Cartesian Therapeutics clears an autoimmune CAR-T trial, starts another Phase 2 and raises $130M' https://lnkd.in/eHtpW7T3 This is an exciting development that expands on tantalizing CAR-T data in autoimmunity first reported in lupus last year. Is autoimmunity the saving grace for the CAR-T field as multiple companies migrate from oncology? The competition will be no less fierce in autoimmunity where mAbs have made significant advances over the years and are truly off-the-shelf products, and cheaper as well. One key question concerns how many CAR-T products can the autoimmunity field accommodate, especially if they are all targeting B cell specific antigens. Perhaps the competitive landscape will be adjudicated by the relative durability of any response. Whereas the durability of mAb function is dictated by standard pharmacokinetics, the durability of CAR-T responses may be longer if they function as an immunomodulatory reset to the immune system. Time and data will tell. #Alloplex #celltherapies #CAR-T #oncologyresearch #cancerresearch

Big News: Provisional Patent Filed for BuChE Inhibitor! We’re excited to announce that Pharmaeconomica BV has filed a provisional patent for our groundbreaking BuChE inhibitor, a key enzyme involved in several neurodegenerative disorders including Alzheimer's. This marks a huge step forward in our mission to develop innovative therapeutics. Powered by our advanced PREDIT platform, this new compound shows great promise in targeting BuChE. PREDICT has been instrumental in predicting the efficacy and safety profiles of our BuChE inhibitor, which ensures a robust and efficient drug discovery process. Huge thanks to our dedicated team and amazing collaborators for making this possible. We invite you to connect with Pharmaeconomica BV and explore potential collaboration opportunities. Together, we can drive innovation and make a significant impact on healthcare. #DrugDiscovery #Pharmaeconomica #BuChEInhibitor #BiotechInnovation #Healthcare #PREDIT #PharmaDevelopment #PatentFiling